Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Several other brokerages also recently commented on IMUX. Roth Capital reissued a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Immunic in a research report on Thursday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Wedbush reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Immunic in a report on Thursday, September 10th. Finally, LADENBURG THALM/SH SH upgraded Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus target price of $35.43.
Get Our Latest Research Report on IMUX
Immunic Stock Performance
Immunic (NASDAQ:IMUX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.36. Sell-side analysts predict that Immunic will post -3.71 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Avidity Partners Management LP raised its stake in Immunic by 42.6% in the first quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after purchasing an additional 2,000,000 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Immunic in the 1st quarter worth approximately $1,020,000. Braidwell LP purchased a new position in Immunic in the 2nd quarter worth approximately $9,914,000. Simplify Asset Management Inc. purchased a new position in Immunic in the 1st quarter worth approximately $487,000. Finally, Connective Capital Management LLC bought a new position in shares of Immunic in the 4th quarter worth $161,000. 51.82% of the stock is currently owned by institutional investors.
About Immunic
Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.
Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.
Further Reading
- Five stocks we like better than Immunic
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
